Abstract
Vascular smooth muscle cells (VSMCs) contraction can be evoked by the rise of cytosolic [Ca2+] owing to transmembrane Ca2+ influx or sarcoplasmic reticulum (SR) Ca2+ release. Although the classical ionotropic role of voltagedependent (L-type) Ca2+ channels (VGCCs) is known, we review here data suggesting a new metabotropic function of VGCCs in vascular smooth muscle cells. VGCCs can trigger Ca2+ release from the SR in the absence of extracellular Ca2+. During depolarization, VGCCs can activate G proteins and phospholipase C (PLC)/inositol 1,4,5-trisphosphate (InsP3) pathway leading to Ca2+ release and arterial contraction. This new metabotropic role of VGCCs, referred as calcium channel-induced Ca2+ release (CCICR), has a major role in tonic VSM contractility, as it links sustained membrane depolarization and Ca2+ channel activation with metabotropic Ca2+ release from the sarcoplasmic reticulum (SR) and tonic smooth muscle contraction. This new role of VGCCs could have a wide functional relevance for the pathogenesis of vasospasms mediated by membrane depolarization and vasoactive agents that can activate VGCCs. Precise understanding of CCICR could help to optimize pharmacological treatments for clinical conditions where Ca2+ channels antagonists are recommended.
Keywords: Vascular smooth muscle, L-type Ca2+ channels, sarcoplasmic reticulum, depolarization-induced Ca2+ release, arterial contraction.
Current Vascular Pharmacology
Title:A New Metabotropic Role for L-type Ca2+ Channels in Vascular Smooth Muscle Contraction
Volume: 11 Issue: 4
Author(s): Juan Urena, Miguel Fernandez-Tenorio, Cristina Porras-Gonzalez, Patricia Gonzalez-Rodriguez, Antonio Castellano and Jose Lopez-Barneo
Affiliation:
Keywords: Vascular smooth muscle, L-type Ca2+ channels, sarcoplasmic reticulum, depolarization-induced Ca2+ release, arterial contraction.
Abstract: Vascular smooth muscle cells (VSMCs) contraction can be evoked by the rise of cytosolic [Ca2+] owing to transmembrane Ca2+ influx or sarcoplasmic reticulum (SR) Ca2+ release. Although the classical ionotropic role of voltagedependent (L-type) Ca2+ channels (VGCCs) is known, we review here data suggesting a new metabotropic function of VGCCs in vascular smooth muscle cells. VGCCs can trigger Ca2+ release from the SR in the absence of extracellular Ca2+. During depolarization, VGCCs can activate G proteins and phospholipase C (PLC)/inositol 1,4,5-trisphosphate (InsP3) pathway leading to Ca2+ release and arterial contraction. This new metabotropic role of VGCCs, referred as calcium channel-induced Ca2+ release (CCICR), has a major role in tonic VSM contractility, as it links sustained membrane depolarization and Ca2+ channel activation with metabotropic Ca2+ release from the sarcoplasmic reticulum (SR) and tonic smooth muscle contraction. This new role of VGCCs could have a wide functional relevance for the pathogenesis of vasospasms mediated by membrane depolarization and vasoactive agents that can activate VGCCs. Precise understanding of CCICR could help to optimize pharmacological treatments for clinical conditions where Ca2+ channels antagonists are recommended.
Export Options
About this article
Cite this article as:
Urena Juan, Fernandez-Tenorio Miguel, Porras-Gonzalez Cristina, Gonzalez-Rodriguez Patricia, Castellano Antonio and Lopez-Barneo Jose, A New Metabotropic Role for L-type Ca2+ Channels in Vascular Smooth Muscle Contraction, Current Vascular Pharmacology 2013; 11 (4) . https://dx.doi.org/10.2174/1570161111311040012
DOI https://dx.doi.org/10.2174/1570161111311040012 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacogenomic Considerations in the Treatment of the Pediatric Cardiomyopathy Called Barth Syndrome
Recent Patents on Biotechnology Serotonin and its Receptors in the Human CNS with New Findings - A Mini Review
Current Medicinal Chemistry Benefits of L-Arginine on Cardiovascular System
Mini-Reviews in Medicinal Chemistry Class- and Molecule-specific Differential Effects of Angiotensin II Type 1 Receptor Blockers
Current Pharmaceutical Design Gender Differences in Response to Therapy for Cardiovascular Diseases
Current Pharmacogenomics and Personalized Medicine Analgesia and Sedation in Mechanical Ventilation in Neonatology
Current Respiratory Medicine Reviews Outcome Prediction after Non-aneurysmal Non-traumatic Subarachnoid Hemorrhage
Current Neurovascular Research Ligand-receptor Engineering and its Application Towards the Complementation of Genetic Disease and Target Identification
Current Topics in Medicinal Chemistry Anti-Apoptotic Effect of Human Telomerase Reverse Transcriptase on Endothelial Cells under Oxidative Stress, Independent of Telomere Elongation and Telomerase Activity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Current Therapeutic Strategies and Future Perspectives for the Prevention of Arterial Thromboembolism: Focus on Atrial Fibrillation
Current Pharmaceutical Design Osteoblastic Responses to LPS, Glucose-oxidised LDL and Minocycline: Therapeutic Targets for Periodontal and Cardiometabolic Diseases
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Formulation and Evaluation of Extended Release Asymmetric Membrane Capsules of Atenolol
Current Drug Delivery Non-Invasive Assessment of Atherosclerosis Risk
Current Drug Targets - Cardiovascular & Hematological Disorders TNF-α and IL-8 in Acute Stroke and the Modulation of these Cytokines by Antiplatelet Agents
Current Neurovascular Research The Discovery and Development of Drug Combinations for the Treatment of Various Diseases from Patent Literature (1980-Present)
Current Topics in Medicinal Chemistry Conference Report: The American Association for the Advancement of Science (AAAS), 180th Annual Meeting Chicago, IL, USA Feb 13-17, 2014 “Meeting Global Challenges: Discoveries & Innovation”
CNS & Neurological Disorders - Drug Targets Recent Advances in the Management of Pulmonary Arterial Hypertension
Current Respiratory Medicine Reviews Alerting Reaction in Office Blood Pressure and Target Organ Damage: An Innocent Phenomenon?
Current Hypertension Reviews Effect of Early Normotension with Olmesartan on Rho-kinase Activity in Hypertensive Patients
Current Vascular Pharmacology Etanercept Improves Cognitive Performance and Increases eNOS and BDNF Expression During Experimental Vascular Dementia in Streptozotocin- induced Diabetes
Current Neurovascular Research